Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
RA Capital Management and affiliated funds filed an amended Schedule 13G reporting their beneficial ownership in Taysha Gene Therapies, Inc. common stock as of June 30, 2026. The RA Capital Healthcare Fund directly holds 23,555,648 shares of common stock and pre-funded warrants exercisable for up to 52,134,718 additional shares.
Because the pre-funded warrants include a Beneficial Ownership Blocker set at 9.99%, only 9,330,594 warrant shares are currently included in beneficial ownership, bringing total counted beneficial ownership to 32,886,242 shares, or 9.99% of Taysha’s common stock. Voting and dispositive power over these securities is delegated to RA Capital, with RA Capital, Peter Kolchinsky, and Rajeev Shah each disclaiming beneficial ownership except for Section 13(d) reporting purposes.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC report beneficial ownership of 16,244,339 shares of Taysha Gene Therapies, Inc. common stock as of June 30, 2026, representing 5.1% of the class. These shares are held with shared voting power over 16,067,509 shares and shared dispositive power over 16,244,339 shares.
Morgan Stanley Capital Services LLC separately reports 16,001,130 shares, equal to 5.0% of the common stock, all with shared voting and dispositive power. The reporting persons classify themselves respectively as a holding company and a broker-dealer and file jointly under a Joint Filing Agreement.
Taysha Gene Therapies, Inc. reported no revenue for the three and six months ended June 30, 2026, compared with $1.99 million and $4.29 million in 2025 driven by prior Astellas collaboration revenue. Operating expenses rose sharply as the company advanced its gene therapy pipeline, with research and development reaching $38.6 million in the quarter and $72.4 million year-to-date, more than double the prior-year periods. Net loss widened to $46.6 million for the quarter and $89.0 million for the first half.
Taysha strengthened its balance sheet through a June 2026 underwritten offering of common stock and pre-funded warrants, generating $215.6 million in net proceeds at a public price of $6.00 per share. Cash and cash equivalents increased to $455.4 million as of June 30, 2026, from $319.8 million at year-end 2025, despite $81.3 million of operating cash outflows in the first half. The company also terminated its Durham manufacturing lease, recognizing a $3.4 million net gain and reducing long-term lease obligations.
Total assets were $470.4 million and total liabilities $83.2 million, including a Trinity term loan carried at fair value of $49.3 million and related success fee derivatives of $1.6 million. Stockholders’ equity increased to $387.3 million from $246.9 million at December 31, 2025, supported by equity financing. Management states that cash on hand is expected to fund planned operations for at least twelve months from issuance of these financial statements, but additional capital will be required to complete development and commercialization activities.
Taysha Gene Therapies, Inc. reported second quarter 2026 results and clinical progress for TSHA-102 in Rett syndrome. Dosing was completed in the REVEAL pivotal trial (N=17) and ASPIRE trial (N=4), with TSHA-102 generally well tolerated across 33 patients with no severe treatment-related SAEs or DLTs. Longer-term REVEAL Part A data showed multi-domain functional gains deepening through at least 12 months post-treatment. The company expanded its commercial-readiness efforts, including a broader manufacturing partnership with Catalent.
Research and development expenses were $38.6 million, up from $20.1 million a year earlier, and general and administrative expenses were $12.1 million versus $8.6 million. Net loss for the quarter was $46.6 million, or $0.13 per share, compared with $26.9 million, or $0.09 per share. Following a $230.0 million follow-on offering, cash and cash equivalents totaled $455.4 million at June 30, 2026, which the company expects will fund operations into the second half of 2028. Topline data from the REVEAL pivotal six-month interim analysis and FDA feedback on the TSHA-102 BLA pathway are anticipated in the first half of 2027.
Taysha Gene Therapies, Inc. director and officer Nagendran Sukumar reported an open-market sale of 200,000 shares of common stock on July 10, 2026 at a weighted average price of $6.24 per share. The shares were sold in multiple trades between $5.99 and $6.52 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. Following the transaction, Sukumar holds 936,410 shares of common stock directly.
Taysha Gene Therapies, Inc. shareholder Sukumar Nagendran filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after 07/10/2026 on Nasdaq. The proposed sale has an aggregate market value of $1,298,000. The filer reports prior sales of 200,000 shares during the past three months for $831,300, and discloses stock option grants of 132,063 shares on 01/02/2024 and 67,937 shares on 01/02/2025.
Taysha Gene Therapies is raising about $200.0 million through an underwritten public offering of common stock and pre-funded warrants. The company is selling 32,500,001 common shares at $6.00 each and pre-funded warrants for 833,333 shares at $5.999 per warrant.
Underwriters can buy up to 5,000,000 additional shares within 30 days. Taysha expects net proceeds of about $187.4 million, or $215.6 million if the option is fully exercised. Management believes this cash, combined with existing funds, will finance operations and capital needs into the second half of 2028.
Taysha Gene Therapies is offering 32,500,001 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 833,333 shares at a public offering price of $6.00 per share (pre-funded warrants priced at $5.999). The offering is expected to close on June 26, 2026, and the company estimates net proceeds of approximately $187.4 million before expenses (approximately $215.6 million if underwriters exercise their full 30-day option for 5,000,000 additional shares). The prospectus supplement cites clinical and regulatory progress for TSHA-102 in Rett syndrome (REVEAL and ASPIRE programs) and states the company had 287,276,885 shares outstanding as of March 31, 2026.
Taysha Gene Therapies is offering up to $200,000,000 of common stock and pre-funded warrants in a subject to completion preliminary prospectus supplement dated June 24, 2026. The offering includes pre-funded warrants exercisable at an exercise price of $0.001 per share. The prospectus references 287,276,885 shares outstanding as of March 31, 2026 and reported cash and cash equivalents of $276.6 million as of that date. Net proceeds are intended to support regulatory and commercial manufacturing development, planned BLA activities and the continued clinical and preclinical development of TSHA-102 and other pipeline candidates, including planned Process Performance Qualification activities initiated in April 2026 and expected completion in the fourth quarter of 2026.
Taysha Gene Therapies reported major clinical and regulatory progress for TSHA-102 in Rett syndrome. The company completed dosing of 17 patients in its REVEAL pivotal trial and shared longer-term Phase 1/2 Part A data in 12 females aged 6–21 years.
Across REVEAL Phase 1/2 and pivotal studies (N=29), TSHA-102 was generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities as of the June 2026 cutoff. In Part A, 100% of patients gained or regained at least one developmental milestone, with 310 total functional gains at ≥12 months, including 31 milestones and 279 additional skill gains.
Regulators have aligned that a 6‑month interim analysis from the pivotal trial may support a potential biologics license application, supplemented by Part A data and safety data from the ASPIRE trial in younger patients. Taysha expects topline interim results and FDA feedback on the BLA pathway in the first half of 2027.